Etern
Shanghai, Shanghai, China
About Etern
Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2024)
- Website: eterntx.comcn
Industries & Categories
Biopharma, Biotechnology
Canonical: https://fsome.com/organization/etern-2520802 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.